Publications by authors named "S Turhal"
Introduction: Most newly diagnosed cancers occur in older adults, and it is important to understand a patient's underlying health status when making treatment decisions. Therefore, clinicians need enhanced competencies and skills to effectively care for this population. However, most clinicians receive minimal to no training in geriatrics.
View Article and Find Full Text PDFArticle Synopsis
- The MONALEESA-7 study is the only phase 3 research on CDK 4-6 inhibitors for premenopausal patients with hormone receptor-positive, HER2 negative metastatic breast cancer, but there is limited data on palbociclib's effectiveness.
- Our multicenter, retrospective study included 319 patients to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment and how dose reduction due to neutropenia affects progression-free survival (PFS).
- Results showed similar median PFS for both drugs (26.83 months for palbociclib and 29.86 months for ribociclib) and no significant impact of dose reduction on effectiveness, with P
Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years.
View Article and Find Full Text PDFThe aim of the study was to evaluate the real-world clinical outcomes of atezolizumab and bevacizumab (Atez/Bev) as the initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65 patients treated with Atez/Bev for advanced HCC from 22 institutions in Turkey between September 2020 and March 2023. Responses were evaluated by RECIST v1.
View Article and Find Full Text PDFAim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS).
Patients And Methods: This multicenter study is based on retrospective review of hospital medical records of patients (≥ 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort.